documentation:oncology:meeting_notes_2019_jun-25
Differences
This shows you the differences between two versions of the page.
| Next revision | Previous revision | ||
| documentation:oncology:meeting_notes_2019_jun-25 [2019/06/26 10:37] – created mgurley | documentation:oncology:meeting_notes_2019_jun-25 [2019/06/27 14:10] (current) – mgurley | ||
|---|---|---|---|
| Line 4: | Line 4: | ||
| **Topics** | **Topics** | ||
| - | * Rimma Belenkaya went over the ETL instructions for ETLing oncology diagnosis | + | * Rimma Belenkaya went over the ETL instructions for ETLing oncology diagnosis |
| * Maxim Moinat raised the issue of whether he should map European tumor registry data to NAACCR or go directly to SNOMED and/or LOINC. | * Maxim Moinat raised the issue of whether he should map European tumor registry data to NAACCR or go directly to SNOMED and/or LOINC. | ||
| - | * It was argued that even though it is less than ideal to map to NAACCR, this is the current right choice. We need to conventionalize our representation of oncology diagnosis and oncology diagnosis modifier structure and semantics to make analyses comparable across institutions. | + | * It was argued that even though it is less than ideal to map to NAACCR, this is the current right choice. We need to conventionalize our representation of oncology diagnosis modifier structure and semantics to make analyses comparable across institutions. |
| - | * It was stated that making NAACCR the standard oncology diagnosis modifier vocabulary | + | * It was stated that making NAACCR the standard oncology diagnosis modifier vocabulary |
| * Maxim Moinat agreed to attempt to map his European tumor registry data to NAACCR. | * Maxim Moinat agreed to attempt to map his European tumor registry data to NAACCR. | ||
| * The group was asked for volunteers to write SQL to derive Hemonc.org oncology drug regimens from low-level DRUG_EXPOSURE and EPISODE oncology diagnosis entries. | * The group was asked for volunteers to write SQL to derive Hemonc.org oncology drug regimens from low-level DRUG_EXPOSURE and EPISODE oncology diagnosis entries. | ||
| * Dmytry Dymshyts expressed doubt about the possibility of derivation of oncology drug regimens from discrete DRUG_EXPOSURE data and EPISODE oncology diagnosis entries. | * Dmytry Dymshyts expressed doubt about the possibility of derivation of oncology drug regimens from discrete DRUG_EXPOSURE data and EPISODE oncology diagnosis entries. | ||
| - | * The group agreed that validation of derivation will need to be compered | + | * The group agreed that validation of derivation will need to be compared |
| * Michael Gurley pointed out that some institutions' | * Michael Gurley pointed out that some institutions' | ||
| * Michael Gurley mentioned that Jeremy Warner (one of the principal architects of Hemonc.org) | * Michael Gurley mentioned that Jeremy Warner (one of the principal architects of Hemonc.org) | ||
documentation/oncology/meeting_notes_2019_jun-25.1561545472.txt.gz · Last modified: by mgurley